LONDON, October 11, 2011 /PRNewswire/ --
PAT and QbD remains a field that still lacks clarity and commonality in understanding. In a recent industry-survey released by Pharma IQ across the PAT and QbD community it was found that 53% of end users said the key reason they were not implementing PAT/QbD was due to a lack of personnel with expertise in the field.
However, Pharma IQ once again opens its doors to industry specialists from the PAT and QbD community and creates an opportunity to learn from leading minds in the industry, increase understanding in companies and cut costs and increase efficiency by learning the best practice approaches to implementing PAT and QbD at the 9th Annual PAT and QbD conference on the 20 - 22 February, 2012, Thistle Marble Arch, London, UK.
For full event information visit: http://www.patandqbd.com/news
Brett Cooper, Research Fellow, MSD Development Laboratories will be speaking at the conference about PAT and QbD within the early development space. On this he mentions: "This is becoming an increasingly important area of interest within MSD."
Nuno Matos, a PAT Specialist from Hovione is also speaking at this industry event and he adds: "I also look forward to discussing the role of the CMO in the integration of QbD/PAT methodologies across the drug substance and drug product supply chain during development and commercial manufacturing."
Furthermore, the conference agenda includes a number of regulatory orientated talks, opportunities to speak directly with regulators during interactive panel discussions and a fantastic panel of speakers with perspectives offered by 3 regulatory bodies.
Media contact: Veronica Araujo
|SOURCE Pharma IQ|
Copyright©2010 PR Newswire.
All rights reserved